about
Targeting heat shock proteins to modulate α-synuclein toxicityCardiovascular gene therapy for myocardial infarctionAAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.The structure of AAVrh32.33, a novel gene delivery vectorWhole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyA single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.Full-length dystrophin reconstitution with adeno-associated viral vectorsGlobal CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Targets for future clinical trials in Huntington's disease: what's in the pipeline?Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retinaLysosomal storage disease: gene therapy on both sides of the blood-brain barrier.An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in miceIntrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Immobilization of FLAG-Tagged Recombinant Adeno-Associated Virus 2 onto Tissue Engineering Scaffolds for the Improvement of Transgene Delivery in Cell Transplants.A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogsHumoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogsExamining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.Gene therapy approaches for lysosomal storage disease: next-generation treatment.Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.A reliable and feasible qPCR strategy for titrating AAV vectorsGenetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector.Inducing immune tolerance: a focus on Type 1 diabetes mellitus.Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy.Recent developments in transposon-mediated gene therapy.Immunological Monitoring to Rationally Guide AAV Gene Therapy.Gene replacement therapy for genetic hepatocellular jaundice.Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.Current and future prospects for hemophilia gene therapy.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.
P2860
Q26827066-F6A56135-9B78-4395-949C-AD1E882A948BQ27014770-F3A0FE16-6F78-4B75-B948-BFEB63B80557Q27324755-CDE55534-9AB3-4227-8BD3-1DDB50227A18Q27682946-63817FA0-E4E8-48CA-8E31-9F5AF3675EE7Q30541880-92118EBA-9642-429F-AFD3-6DFDBA5101BEQ30559496-0443C110-F205-44EE-BC46-DBE057CA1792Q33782799-84E3AD5B-B5CA-4FB2-8DE6-153062935C39Q33870720-C528CCFB-C70F-4C8A-8727-D1A436001DD1Q33881920-8577C0DB-3812-4BE2-83AF-5091CC0DDE44Q33938435-D8AB7EBC-F988-4CDB-9563-386FBA13A163Q34435001-5D3BD097-3496-4C84-8BFB-A7E99CB1EC0FQ34566454-27AC8838-98EF-4AEA-B6A7-B8A65F1190DBQ34673011-7A71378D-C27B-4A85-888C-CD3960D771EBQ35034401-32C96AD5-939D-444D-85F3-CCEDCE1CF1AFQ35091621-5D582B80-79F3-4579-8B21-8B454FF34CDCQ35399100-9F82BCE6-B129-4AC9-8B23-E5FAD805A186Q35450610-4590645C-08C9-4663-8CEB-2B90090A60C9Q35451204-887EEFDF-46FA-4D26-B4D4-CED552E663FDQ35649962-D137A889-E71D-4798-BED9-F91EAD629D74Q35751578-5826BE83-E5F0-4041-952A-7091213EB7C0Q35823873-4C1D52B9-98A0-4C04-9A31-CBDA69064470Q35960506-162079C1-D695-41BF-8DC7-1CA1DED5F4B7Q36085401-56C35AF6-AF75-4187-9531-E23A77BD07BDQ36147475-30E41831-B16C-4150-97FD-49015D7C7628Q36582796-99AFF66A-1F08-42F2-8C58-825395E28BDBQ36659250-CA8D7D81-229D-4C05-8D51-2FE96418A5A0Q36709834-17946D52-C6BE-4A2D-B1BF-B800896F57EBQ36740271-69BC2BC0-7B49-4317-9B72-F874D25E91A5Q36759915-2651C1E2-2B97-46ED-8F3A-6C9ED81B9FFEQ36996899-C84BA6BF-D364-4FD1-9FFE-B1CDC367A056Q37043485-EE8D7594-B27D-480E-8532-767BA9515A5CQ37542678-23202FDF-1928-4361-8375-D0E9DF31D9EFQ37685861-D81B2DCB-078B-40F6-BEDD-7FA3CA823966Q37965158-D38FD0A7-4BF7-47B2-BD8C-659D11E01B6EQ38017202-865F204F-A212-46D9-B545-08F33DAFACBCQ38142098-AE9548B5-59A9-45BF-A5E3-8C272DFE8D13Q38260248-69064A98-D6A0-4E13-A2D9-D3B1EF6D387DQ38712002-0410E5ED-D9B6-42A4-B978-4126CA32BD7EQ38827606-C3CD3C79-8BAA-49D5-BEA9-0ED7E29CDA25Q38856794-962BD377-797D-4D08-8C03-40A74F821982
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune responses to AAV in clinical trials.
@en
Immune responses to AAV in clinical trials.
@nl
type
label
Immune responses to AAV in clinical trials.
@en
Immune responses to AAV in clinical trials.
@nl
prefLabel
Immune responses to AAV in clinical trials.
@en
Immune responses to AAV in clinical trials.
@nl
P1433
P1476
Immune responses to AAV in clinical trials.
@en
P2093
Federico Mingozzi
Katherine A High
P304
P356
10.2174/156652311796150354
P407
P577
2011-08-01T00:00:00Z